Cure First Expands Cancer Precision Medicine Access with New Washington Lab
Cure First to More Than Double PARIS Test Capacity, Expanding Functional Precision Medicine Access for Patients With Difficult-to-Treat Cancers Cure First, a Seattle-based 501(c)(3) nonprofit organization focused on expanding access…
Immunis Named Semifinalist in $1.5M Healthy Longevity Global Competition
Immunis Named Semifinalist in National Academy of Medicine’s Healthy Longevity Global Competition for Muscle Health Innovation Immunis, Inc., a clinical-stage biotechnology company developing multi-active biologics designed to restore muscle health…
GC Biopharma to Present Expanded ALYGLO® Phase 3 Safety Data at IgNS 2026
GC Biopharma to Present New IVIG Product Analyses and Host Patient Advocacy Symposium at IgNS 2026 Conference GC Biopharma USA, Inc., a company specializing in plasma-derived products, has announced plans…
IgniteData and RealTime Partner to Expand Clinical Trial Data Transfer in Global Markets
IgniteData and RealTime eClinical Solutions Partner to Streamline Clinical Trial Data Transfers Through Archer Platform IgniteData, a provider of intelligent clinical trial data automation technology, and RealTime eClinical Solutions, a…
Fortitude Biomedicines to Present FTB-918 Axial Spondyloarthritis Data at ACR Convergence 2026
Fortitude Biomedicines to Present FTB-918 Preclinical Data for Axial Spondyloarthritis at ACR Convergence 2026 Fortitude Biomedicines, Inc., a biopharmaceutical company focused on developing precision antibody-based therapies for autoimmune diseases and…
Tortugas Neuroscience Reports Positive Phase 2b Results for Obuprazine in Schizophrenia
Tortugas Neuroscience Reports Positive Phase 2b Results for Obuprazine in Schizophrenia, Showing Significant Symptom Improvements and Rapid Clinical Response Tortugas Neuroscience, a clinical-stage biotechnology company focused on developing transformative therapies…
VITALiS Selects Applied BioCode for Molecular Gastrointestinal Pathogen Panel Testing
VITALiS Expands Collaboration With Applied BioCode to Support In-House Gastrointestinal Pathogen Testing VITALiS and Applied BioCode have announced an expanded collaboration aimed at increasing the adoption of gastrointestinal (GI) pathogen…
Rubedo Life Sciences Reports RLS-1496 Phase 1b Data Showing Reduced Skin Epigenetic Age and Inflammation
Rubedo Life Sciences Reports Phase 1b Data Showing Reduced Skin Epigenetic Age and Inflammatory Biomarkers With RLS-1496 Rubedo Life Sciences, a clinical-stage biotechnology company developing therapeutics designed to rejuvenate cellular…
Stoke Therapeutics Presents STK-002 Disease-Modifying Data in ADOA at AAO 2026
Stoke Therapeutics Presents STK-002 Preclinical and Clinical Data at AAO 2026, Advancing RNA-Based Approach for Autosomal Dominant Optic Atrophy Stoke Therapeutics, Inc., a biotechnology company focused on restoring protein expression…
Catalent and Mantra Sign Commercial Supply Agreement for Single-Serve Oral Gel Portfolio
Catalent Partners with Mantra to Develop and Manufacture Single-Serve OTC Oral Gel Products Catalent, Inc., a leading global contract development and manufacturing organization (CDMO) dedicated to helping people live better…
TG Therapeutics Publishes Five-Year Comparative Analysis of BRIUMVI, Ocrelizumab and Ofatumumab in Relapsing MS
TG Therapeutics Publishes Five-Year Comparative Analysis Showing Favorable Long-Term Outcomes for BRIUMVI in Relapsing Multiple Sclerosis TG Therapeutics, Inc. has announced the publication of results from a five-year matching-adjusted indirect…
Bristol Myers Squibb’s Phase 3 ALOFT-IPF Trial of Admilparant Meets Primary Endpoint in IPF Patients
Bristol Myers Squibb Reports Positive Phase 3 ALOFT-IPF Results for Admilparant in Idiopathic Pulmonary Fibrosis Bristol Myers Squibb has announced topline results from its pivotal Phase 3 ALOFT-IPF clinical trial…